Hepatitis B and C virus infection and risk of haematological malignancies

Aldo Marrone; Marco Ciotti; Luca Rinaldi; Luigi Elio Adinolfi; Marc Ghany

doi:10.1111/jvh.13183

Hepatitis B and C virus infection and risk of haematological malignancies

J Viral Hepat. 2020 Jan;27(1):4-12. doi: 10.1111/jvh.13183. Epub 2019 Aug 13.

Authors

Aldo Marrone¹, Marco Ciotti², Luca Rinaldi¹, Luigi Elio Adinolfi¹, Marc Ghany³

Affiliations

¹ Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy.
² Laboratory of Clinical Microbiology and Virology, Polyclinic Tor Vergata Foundation, Rome, Italy.
³ Liver Diseases Branch, Division of Digestive Diseases and Nutrition, National Institute of Diabetes, Digestive and Kidney Diseases (NIDDK), National Institutes of Health (NIH), Bethesda, Maryland, USA.

PMID: 31325404
DOI: 10.1111/jvh.13183

Abstract

Hepatitis B virus (HBV) and hepatitis C virus (HCV) are classified as oncogenic human viruses. Chronic HBV and HCV infections are associated with higher risk of haematological malignancy development. Direct and indirect oncogenic mechanisms have been demonstrated for both HBV and HCV in several studies. HCV and overt/occult HBV infections in patients with oncohaematological disease constitute an impediment and a threat during immunosuppressive chemotherapy treatment. We review the HBV and HCV oncogenic mechanisms and the impact and the safety of antiviral treatment in patients with haematological malignancies.

Keywords: haematological malignancies; hepatitis B virus (HBV); hepatitis C virus (HCV).

Publication types

Review

MeSH terms

Antiviral Agents / therapeutic use
Hematologic Neoplasms / virology*
Hepatitis B / complications*
Hepatitis B / drug therapy
Hepatitis C / complications*
Hepatitis C / drug therapy
Hepatitis C, Chronic / complications
Humans
Risk Factors
Virus Activation / drug effects

Substances

Antiviral Agents